This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Horsman, M. R. Articles by Siemann, D. W. Search for Related Content PubMed PubMed Citation Articles by Horsman, M. R. Articles by Siemann, D. W. Related Collections Therapeutics and Targets Therapeutics and Targets: Experimental Therapeutics– Biologics Clinical Research: Clinical Trials

Pathophysiologic Effects of Vascular-Targeting Agents and the Implications for Combination with Conventional Therapies

¹ Department of Experimental Clinical Oncology, Aarhus University Hospital, Aarhus, Denmark and ² Department of Radiation Oncology, University of Florida, Gainesville, Florida

Requests for reprints: Michael R. Horsman, Department of Experimental Clinical Oncology, Aarhus University Hospital, Nørrebrogade 44, DK-8000 Aarhus C, Denmark. Phone: 45-89492622; Fax: 45-86197109; E-mail: mike{at}oncology.dk.

A functional vascular supply is critical for the continued growth and development of solid tumors. It also plays a major role in metastatic spread of tumor cells. This importance has led to the concept of targeting the vasculature of the tumor as a form of cancer therapy. Two major types of vascular-targeting agent (VTA) have now emerged: those that prevent the angiogenic development of the neovasculature of the tumor and those that specifically damage the already established tumor vascular supply. When used alone neither approach readily leads to tumor control, and so, for VTAs to be most successful in the clinic they will need to be combined with more conventional therapies. However, by affecting the tumor vascular supply, these VTAs should induce pathophysiologic changes in variables, such as blood flow, pH, and oxygenation. Such changes could have negative or positive influences on the tumor response to more conventional therapies. This review aims to discuss the pathophysiologic changes induced by VTAs and the implications of these effects on the potential use of VTAs in combined modality therapy. (Cancer Res 2006; 66(24): 11520-39)

This article has been cited by other articles:

				L. G. Daenen, Y. Shaked, S. Man, P. Xu, E. E. Voest, R. M. Hoffman, D. J. Chaplin, and R. S. Kerbel Low-dose metronomic cyclophosphamide combined with vascular disrupting therapy induces potent antitumor activity in preclinical human tumor xenograft models Mol. Cancer Ther., October 1, 2009; 8(10): 2872 - 2881. [Abstract] [Full Text] [PDF]

				T. Meyer, A. M. Gaya, G. Dancey, M. R.L. Stratford, S. Othman, S. K. Sharma, D. Wellsted, N. J. Taylor, J. J. Stirling, L. Poupard, et al. A Phase I Trial of Radioimmunotherapy with 131I-A5B7 Anti-CEA Antibody in Combination with Combretastatin-A4-Phosphate in Advanced Gastrointestinal Carcinomas Clin. Cancer Res., July 1, 2009; 15(13): 4484 - 4492. [Abstract] [Full Text] [PDF]

				G M Tozer, C Kanthou, G Lewis, V E Prise, B Vojnovic, and S A Hill Tumour vascular disrupting agents: combating treatment resistance Br. J. Radiol., October 1, 2008; 81(Special_Issue_1): S12 - S20. [Abstract] [Full Text] [PDF]

				D. Zhao, E. Richer, P. P. Antich, and R. P. Mason Antivascular effects of combretastatin A4 phosphate in breast cancer xenograft assessed using dynamic bioluminescence imaging and confirmed by MRI FASEB J, July 1, 2008; 22(7): 2445 - 2451. [Abstract] [Full Text] [PDF]

				G. M. Tozer, S. Akerman, N. A. Cross, P. R. Barber, M. A. Bjorndahl, O. Greco, S. Harris, S. A. Hill, D. J. Honess, C. R. Ireson, et al. Blood Vessel Maturation and Response to Vascular-Disrupting Therapy in Single Vascular Endothelial Growth Factor-A Isoform-Producing Tumors Cancer Res., April 1, 2008; 68(7): 2301 - 2311. [Abstract] [Full Text] [PDF]

				J. B. Garrison, Y.-J. Shaw, C.-S. Chen, and N. Kyprianou Novel Quinazoline-Based Compounds Impair Prostate Tumorigenesis by Targeting Tumor Vascularity Cancer Res., December 1, 2007; 67(23): 11344 - 11352. [Abstract] [Full Text] [PDF]

				F. B. Furnari, T. Fenton, R. M. Bachoo, A. Mukasa, J. M. Stommel, A. Stegh, W. C. Hahn, K. L. Ligon, D. N. Louis, C. Brennan, et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment Genes & Dev., November 1, 2007; 21(21): 2683 - 2710. [Abstract] [Full Text] [PDF]

				B. M. Fenton and S. F. Paoni The Addition of AG-013736 to Fractionated Radiation Improves Tumor Response without Functionally Normalizing the Tumor Vasculature Cancer Res., October 15, 2007; 67(20): 9921 - 9928. [Abstract] [Full Text] [PDF]

				J. Overgaard Hypoxic Radiosensitization: Adored and Ignored J. Clin. Oncol., September 10, 2007; 25(26): 4066 - 4074. [Abstract] [Full Text] [PDF]

				S. Senan and E. F. Smit Design of Clinical Trials of Radiation Combined with Antiangiogenic Therapy Oncologist, April 1, 2007; 12(4): 465 - 477. [Abstract] [Full Text] [PDF]